一项关于日本疫苗短缺期间 17D-204 黄热病疫苗安全性的全国前瞻性队列研究。
A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan.
机构信息
Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
Division of Quarantine and Sanitation, Chubu Airport Quarantine Office, Nagoya Quarantine Station, Nagoya 479-0881, Japan.
出版信息
J Travel Med. 2023 Apr 5;30(2). doi: 10.1093/jtm/taac070.
In response to the vaccine shortage of yellow fever vaccine (YF-VAX) due to manufacturing delays, the unapproved 17D-204 YF-VAX was used as an investigator-initiated clinical trial in Japan. The vaccine was administered to 11 279 participants in 19 YF vaccination centres in Japan, and few serious adverse events were observed.
由于黄热病疫苗（YF-VAX）的生产延迟，导致疫苗短缺，日本因此开展了一项研究者发起的临床试验，使用了未经批准的 17D-204 YF-VAX。该疫苗在日本的 19 个 YF 疫苗接种中心对 11279 名参与者进行了接种，观察到的严重不良事件很少。
Zotero 插件